Toradol: Uses, Dosage & Side Effects

What Is Toradol and What Is It Used For?

Toradol is the original brand name under which the pyrrolizine carboxylic acid derivative ketorolac tromethamine was first marketed by F. Hoffmann-La Roche after receiving approval from the U.S. Food and Drug Administration (FDA) on 30 November 1989. Ketorolac was initially synthesized and developed by Syntex Corporation in the early 1980s, and its unique analgesic potency quickly established it as an important non-opioid option in the management of acute pain. Although numerous generic ketorolac products are now available worldwide, the name Toradol remains strongly associated with the injectable formulation, particularly in the United States, Canada, Italy, and other Western markets where the brand has been prescribed for more than three decades.

Chemically, ketorolac tromethamine is the tromethamine (tris) salt of ketorolac, a racemic mixture containing equal proportions of the R-(+) and S-(-) enantiomers. Nearly all of the analgesic and anti-inflammatory activity resides in the S-(-) enantiomer, which is roughly 100 times more potent at inhibiting cyclooxygenase than its R-(+) counterpart. The full molecular structure, C₁₉H₂₄N₂O₆ with a molecular weight of 376.41 g/mol, places Toradol within the heterocyclic acetic acid family of NSAIDs, alongside indomethacin and diclofenac.

As a non-selective NSAID, Toradol produces its therapeutic effects primarily through the inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. These enzymes catalyze the rate-limiting step in the conversion of arachidonic acid into prostaglandins, which are lipid mediators central to inflammation, peripheral pain signaling, and fever generation. By suppressing prostaglandin synthesis, Toradol produces potent analgesic, moderate anti-inflammatory, and antipyretic effects. What distinguishes Toradol from most other NSAIDs is its exceptionally strong analgesic activity. While typical NSAIDs provide moderate pain relief, multiple well-designed randomized controlled trials have shown that a single 30 mg intramuscular dose of Toradol produces analgesia equivalent to approximately 10–12 mg of intramuscular morphine or 50–100 mg of intramuscular meperidine (pethidine), placing it among the most potent non-opioid analgesics available in clinical practice.

The explanation for Toradol's unusually strong analgesic activity lies in its preferential inhibition of peripheral COX enzymes at sites of tissue injury and inflammation. By suppressing prostaglandin E2 (PGE2) production at the site of surgical trauma, fracture, visceral inflammation, or muscle strain, Toradol effectively reduces the sensitization of peripheral nociceptors (pain receptors) and limits the transmission of pain signals to the central nervous system. This peripheral mechanism differs fundamentally from that of centrally acting analgesics such as opioids, which activate mu-opioid receptors within the brain and spinal cord. Because Toradol does not cross the blood-brain barrier to any clinically meaningful extent and does not engage opioid pathways, it provides powerful pain relief without the respiratory depression, sedation, euphoria, constipation, or dependence potential associated with opioid analgesics.

Toradol injection is specifically indicated for the short-term management of moderate to severe acute pain that would otherwise require opioid-level analgesia. The most frequent clinical indications include:

• Postoperative pain management: Toradol is one of the most widely used NSAIDs in the perioperative setting, including after orthopedic, abdominal, gynecological, urological, and dental surgery. It is routinely incorporated into multimodal analgesia protocols that combine local anesthetics, paracetamol (acetaminophen), and reduced-dose opioids. Meta-analyses of postoperative pain trials have consistently demonstrated that Toradol reduces total opioid consumption by approximately 30–50%, shortens time to ambulation, and reduces opioid-related side effects such as nausea, sedation, and ileus.
• Renal colic (ureteral stones): Toradol is widely considered first-line or co-first-line therapy for acute renal colic, with large randomized trials (including the Cochrane review of NSAIDs for renal colic) showing that it is at least as effective as intravenous morphine and often superior in reducing nausea, vomiting, and the need for rescue analgesia. The rationale for superior efficacy in renal colic is mechanistic: prostaglandin inhibition reduces ureteral smooth muscle spasm and decreases glomerular filtration pressure, directly addressing the pathophysiology of colicky pain.
• Acute musculoskeletal pain: Severe pain from fractures, dislocations, sprains, and soft-tissue injuries responds well to Toradol, particularly in the emergency department, where rapid onset of analgesia is essential.
• Acute migraine and primary headache: Parenteral Toradol is an established rescue therapy for severe migraine and medication-overuse headache in emergency department protocols. Unlike triptans, it is safe in patients with cardiovascular risk factors (though cardiovascular contraindications still apply), and unlike opioids, it carries no dependence risk.
• Biliary colic and acute pancreatitis: Toradol is used for symptomatic management of biliary colic, with some studies suggesting it may even slow disease progression in acute pancreatitis by reducing pancreatic duct pressure through prostaglandin inhibition.
• Sickle cell vaso-occlusive crisis (adjunct): As part of multimodal analgesia for sickle cell pain crisis, Toradol is sometimes used to reduce opioid burden, although renal monitoring is particularly important in this population.

It is absolutely critical to understand that Toradol injection is intended only for short-term use. The parenteral formulation is strictly limited to a maximum treatment duration of 2 days. If analgesic therapy is required beyond this window, patients may be transitioned to oral ketorolac for a combined maximum of 5 days of total ketorolac exposure. This time restriction was not arbitrary but was established following post-marketing surveillance data collected throughout the 1990s that demonstrated a sharp, dose- and duration-dependent increase in serious adverse effects, particularly gastrointestinal hemorrhage, when Toradol was used for longer periods. Regulatory agencies worldwide — including the FDA, European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA, UK), Health Canada, and Therapeutic Goods Administration (TGA, Australia) — have codified these duration limits into prescribing information.

What Should You Know Before Taking Toradol?

Contraindications

Toradol has a more extensive list of contraindications than most NSAIDs, reflecting its high analgesic potency and corresponding risk profile. Healthcare providers must systematically screen all candidates for Toradol therapy against these contraindications; administering Toradol to an unsuitable patient can produce serious or fatal complications. The contraindications below are absolute and represent situations in which Toradol should never be prescribed.

Toradol must not be used in patients with active peptic ulcer disease, active gastrointestinal bleeding, or a history of NSAID-induced gastrointestinal ulceration or perforation. The rationale is mechanistic: NSAIDs, including Toradol, suppress the synthesis of protective prostaglandins (especially PGE2 and prostacyclin) in the gastric and duodenal mucosa. These prostaglandins are responsible for maintaining mucosal blood flow, stimulating mucus and bicarbonate secretion, and promoting epithelial regeneration. In their absence, the mucosal barrier becomes vulnerable to hydrochloric acid, pepsin, and bile reflux, creating a high risk of erosion, ulceration, and potentially catastrophic hemorrhage or perforation. Toradol is associated with a higher incidence of upper gastrointestinal bleeding than most other NSAIDs, and this risk can be life-threatening.

Patients with moderate to severe renal impairment (serum creatinine above 442 µmol/L, or creatinine clearance below 30 ml/min) must not receive Toradol. Under normal physiological conditions, renal blood flow is largely independent of prostaglandins, but when effective circulating volume is reduced — as in dehydration, heart failure, cirrhosis, or volume depletion from diuretics — the kidneys rely heavily on vasodilator prostaglandins (PGE2 and PGI2) to maintain adequate glomerular perfusion. By blocking prostaglandin synthesis, Toradol can precipitate acute kidney injury in susceptible patients. Additionally, more than 90% of ketorolac and its metabolites are eliminated renally; in renal impairment, drug accumulation increases systemic exposure and toxicity.

Toradol is also contraindicated in patients with hypovolemia, dehydration, or clinically significant volume depletion from any cause. These conditions predispose to acute renal failure when prostaglandin-mediated vasodilation is blocked. Adequate hydration must be ensured before Toradol administration, and the patient should be monitored for urine output and renal function during therapy.

The drug is absolutely contraindicated in the perioperative period of coronary artery bypass graft (CABG) surgery. Large randomized trials and meta-analyses have demonstrated that both non-selective and COX-2 selective NSAIDs are associated with a significant increase in the risk of myocardial infarction, stroke, and deep vein thrombosis in patients undergoing CABG. This contraindication is a class effect applying to all NSAIDs and is a formal black-box warning on the Toradol label.

Known hypersensitivity to ketorolac tromethamine, aspirin, or any other NSAID is a clear contraindication. NSAID hypersensitivity reactions can include bronchospasm, angioedema, urticaria, rhinitis, and severe anaphylaxis. Cross-reactivity among NSAIDs is common because the reactions are often mediated by the shared pharmacologic mechanism (COX-1 inhibition shifts arachidonic acid metabolism toward leukotriene production). Patients with the Samter triad — aspirin-exacerbated respiratory disease (nasal polyps, asthma, and aspirin or NSAID sensitivity) — are at particularly high risk of severe respiratory reactions.

Toradol is contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis (bleeding disorders), or incomplete hemostasis after surgery. Because ketorolac inhibits platelet aggregation through reversible COX-1 inhibition, it can prolong bleeding time and significantly exacerbate any ongoing hemorrhage. It is likewise contraindicated as a prophylactic analgesic before major surgery and during the intraoperative period, as well as in patients with high risk of postoperative bleeding.

Toradol must not be used in advanced hepatic impairment, and use should be avoided during labor and delivery because inhibition of prostaglandin synthesis may delay or prolong labor and is associated with premature closure of the fetal ductus arteriosus. Administration of Toradol is also not recommended in nursing mothers, given the passage of the drug into breast milk.

Warnings and Precautions

Even in patients without absolute contraindications, Toradol must be prescribed cautiously at the lowest effective dose for the shortest possible duration. The following warnings and precautions apply to all patients receiving this medication.

Gastrointestinal risk: All NSAIDs carry gastrointestinal risk, but Toradol is associated with a disproportionately elevated risk compared with most other NSAIDs. Risk factors that further amplify the likelihood of gastrointestinal complications include advanced age (especially over 65 years), history of peptic ulcer disease or gastrointestinal bleeding, concomitant corticosteroid or anticoagulant therapy, smoking, excessive alcohol intake, Helicobacter pylori infection, and longer NSAID treatment. Serious gastrointestinal bleeding can occur without prior symptoms or warning signs and can be rapidly fatal. Patients must be advised to report any black tarry stools, coffee-ground emesis, or sudden abdominal pain immediately.

Cardiovascular risk: NSAIDs as a class, including Toradol, may increase the risk of serious cardiovascular thrombotic events such as myocardial infarction and stroke. This risk is dose- and duration-dependent and may be greater in patients with pre-existing cardiovascular disease or risk factors. Toradol should be avoided or used with extreme caution in patients with a history of ischemic heart disease, cerebrovascular disease, peripheral arterial disease, heart failure, or uncontrolled hypertension.

Renal effects: Toradol should be used cautiously in patients with any degree of renal impairment, dehydration, volume depletion, heart failure, or cirrhosis. Elderly patients are particularly susceptible to NSAID-related renal toxicity. Pre-treatment assessment of renal function (serum creatinine, estimated glomerular filtration rate) is recommended, and in at-risk patients, renal function should be monitored during therapy. Patients should be encouraged to maintain adequate oral or intravenous hydration.

Bleeding and hemostasis: Toradol inhibits platelet aggregation (COX-1-mediated inhibition of thromboxane A2 synthesis) and may prolong bleeding time. This platelet effect is reversible and lasts approximately 24–48 hours after the last dose. Toradol should be used cautiously in patients with coagulation disorders, those receiving anticoagulant therapy, or those undergoing procedures with a high risk of bleeding.

Hypersensitivity and anaphylaxis: Severe hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, have been reported with ketorolac and can occur even in patients with no prior history of NSAID sensitivity. Patients should be monitored closely during the first administration and instructed to report any signs of allergic reaction immediately.

Hepatic effects: Borderline elevations of one or more liver enzymes may occur in up to 15% of NSAID-treated patients. Meaningful elevations (more than 3 times the upper limit of normal) are less common. Rarely, severe hepatic reactions including jaundice, fulminant hepatitis, hepatic necrosis, and hepatic failure have been reported. Toradol should be discontinued immediately if clinical signs of liver dysfunction or systemic manifestations (e.g., eosinophilia, rash) appear.

Pregnancy and Breastfeeding

Toradol is contraindicated during the third trimester of pregnancy (from week 28 onwards) and during labor and delivery. NSAID use during late pregnancy is associated with several serious fetal and neonatal risks. The most significant of these is premature closure of the ductus arteriosus, a fetal vascular shunt that must remain patent until birth. Premature closure can cause persistent pulmonary hypertension of the newborn, a potentially life-threatening condition. In addition, NSAID use during the third trimester is linked to oligohydramnios (low amniotic fluid) due to reduced fetal urine production, fetal and neonatal renal dysfunction, and, with prolonged use, fetal renal failure. Finally, by inhibiting uterine contractions and prolonging bleeding time, Toradol can delay or prolong labor and increase the risk of peripartum hemorrhage.

During the first and second trimesters of pregnancy, Toradol should be used only if the potential benefit clearly outweighs the potential risk to the fetus. Animal reproduction studies with ketorolac demonstrated evidence of increased peri-implantation loss and decreased fetal weight at maternally toxic doses, though no major teratogenic effects have been clearly established. Large-scale epidemiologic studies have raised concerns about possible associations between early NSAID exposure and miscarriage, though the data remain inconsistent. There are no adequate and well-controlled studies of Toradol in pregnant women, and the medication should be avoided unless clearly necessary.

Ketorolac is excreted in human breast milk in small quantities. A study of 10 lactating women receiving oral ketorolac 10 mg four times daily measured peak milk concentrations of approximately 7.3 ng/ml, corresponding to an estimated infant daily dose of less than 0.4% of the maternal weight-adjusted dose. Although the relative infant dose is low, the potential for serious adverse reactions in nursing infants and the lack of comprehensive safety data warrant caution. Most national prescribing guidelines recommend avoiding Toradol during breastfeeding, and the decision to discontinue nursing or the drug should be made considering the importance of the medication to the mother.

How Does Toradol Interact with Other Drugs?

Drug interactions are a critical clinical consideration when prescribing Toradol, because the medication is typically administered in acute care settings where patients may be receiving multiple concurrent therapies. The following interactions are among the most clinically important.

Major Interactions

Anticoagulants (warfarin, heparin, direct oral anticoagulants): Toradol significantly increases the risk of bleeding when combined with anticoagulant medications. Several mechanisms contribute: Toradol inhibits platelet aggregation through COX-1 inhibition; it can displace warfarin from plasma protein binding sites, transiently increasing the free (active) concentration of warfarin; and it independently increases the risk of gastrointestinal ulceration and bleeding, which compounds the anticoagulant effect. If concomitant use is unavoidable, close monitoring of the international normalized ratio (INR) and clinical signs of bleeding is mandatory, and the patient should be informed of the warning signs of hemorrhage.

Other NSAIDs (including low-dose aspirin): The concomitant use of Toradol with any other NSAID is contraindicated. Combining two or more NSAIDs provides no additional analgesic benefit but substantially raises the risk of serious gastrointestinal bleeding, ulceration, and perforation. Even low-dose aspirin for cardiovascular prophylaxis increases gastrointestinal risk when combined with Toradol. When a patient requires aspirin for cardiovascular protection, the decision to administer Toradol must be weighed carefully, and gastroprotection with a proton-pump inhibitor should be considered.

Pentoxifylline: Concurrent use of Toradol with pentoxifylline (a hemorrheologic agent used for peripheral arterial disease) is contraindicated because of a significantly increased risk of bleeding. Both drugs affect platelet function, and their combination can prolong bleeding time to clinically dangerous levels.

Lithium: NSAIDs, including Toradol, can increase serum lithium concentrations by reducing renal lithium clearance. The mechanism involves inhibition of renal prostaglandin synthesis, which normally promotes sodium and water excretion; when prostaglandins are suppressed, sodium reabsorption increases in the proximal tubule, and lithium reabsorption rises in parallel. Serum lithium levels can increase substantially, leading to toxicity manifested as tremor, ataxia, confusion, and, in severe cases, seizures. Patients receiving both lithium and Toradol must have serum lithium levels monitored closely, and the lithium dose may need adjustment.

Methotrexate: Toradol can reduce the renal clearance of methotrexate, elevating methotrexate plasma concentrations and potentially precipitating severe toxicity. This interaction is particularly dangerous with high-dose methotrexate regimens used in oncology, where even modest reductions in clearance can produce life-threatening bone marrow suppression, mucositis, and hepatotoxicity. The combination should be strictly avoided with high-dose methotrexate; in patients receiving low-dose methotrexate for rheumatoid arthritis or psoriasis, extreme caution and close clinical monitoring are required.

Probenecid: Probenecid significantly inhibits the renal excretion of ketorolac, roughly doubling its plasma concentration and prolonging its half-life. Concurrent use is contraindicated in most prescribing guidelines due to the unpredictable increase in systemic exposure and the associated risk of adverse effects.

Minor Interactions

ACE inhibitors and ARBs: Toradol may reduce the antihypertensive effect of ACE inhibitors (e.g., enalapril, ramipril, lisinopril) and angiotensin II receptor blockers (ARBs, e.g., losartan, valsartan, candesartan). The mechanism involves inhibition of renal prostaglandin synthesis, which is necessary to maintain renal perfusion in patients taking these medications, particularly those with reduced effective circulating volume. The triple combination of an NSAID, an ACE inhibitor or ARB, and a diuretic — the so-called “triple whammy” — poses an especially high risk of acute kidney injury and hyperkalemia, and should be avoided when possible.

Diuretics: NSAIDs can reduce the diuretic and antihypertensive effects of both loop diuretics (e.g., furosemide, bumetanide) and thiazide diuretics (e.g., hydrochlorothiazide) by inhibiting renal prostaglandin-mediated natriuresis. This can lead to fluid retention, worsening hypertension, and decompensation of heart failure. The risk of acute kidney injury also rises, particularly in combination with ACE inhibitors or ARBs.

Selective serotonin reuptake inhibitors (SSRIs): SSRIs such as fluoxetine, sertraline, and paroxetine impair platelet serotonin uptake, which is important for normal platelet aggregation. When combined with Toradol, which inhibits platelet function through COX-1 inhibition, the risk of gastrointestinal bleeding is approximately doubled. Patients receiving both medications should be monitored carefully, and gastroprotection should be considered in patients with additional risk factors.

Corticosteroids: Concurrent systemic corticosteroids (e.g., prednisolone, dexamethasone) increase the risk of gastrointestinal ulceration and bleeding. Corticosteroids impair wound healing and mucosal repair, while NSAIDs such as Toradol suppress the protective prostaglandin barrier, creating synergistic mucosal vulnerability.

Aminoglycoside antibiotics: NSAIDs can reduce the renal clearance of aminoglycosides (e.g., gentamicin, tobramycin), potentially elevating plasma levels and increasing the risk of nephrotoxicity and ototoxicity. Therapeutic drug monitoring is advised in patients receiving both agents.

What Is the Correct Dosage of Toradol?

Adults (Under 65 Years)

For adult patients under 65 years of age with normal renal function and body weight above 50 kg, the recommended dose of Toradol is 30 mg administered intramuscularly (IM) or intravenously (IV) as a single dose, which may be repeated every 6 hours as needed for pain relief. The maximum daily dose by the parenteral route is 120 mg (four doses of 30 mg in 24 hours). For intravenous bolus administration, the injection should be given slowly over a minimum of 15 seconds to minimize venous irritation. Intramuscular injections should be given deeply into a large muscle mass (e.g., the dorsogluteal or vastus lateralis muscle), with the injection site rotated between doses to reduce local tissue irritation.

Some protocols use a loading dose of 60 mg IM as a single injection for initial pain control in particularly severe acute pain; however, this higher loading dose is not universally recommended and is generally reserved for muscular patients with excellent renal function. The onset of analgesic action following intramuscular injection typically occurs within 30 minutes, with peak effect at approximately 1–2 hours and a duration of action of 4–6 hours. Intravenous administration provides a faster onset, with pain relief often beginning within 10–30 minutes. In the postoperative setting, IV Toradol is often preferred for its more rapid onset and the convenience of administration through an existing intravenous line or as part of a patient-controlled analgesia (PCA) regimen.

Children

Pediatric use of Toradol varies by regulatory jurisdiction. In many countries, including the United States, injectable ketorolac is approved for single-dose use in children aged 2 years and older for the short-term management of moderate to severe postoperative pain. When used in pediatric patients, the recommended dose is typically 0.5 mg/kg IM or IV (up to a maximum of 15 mg per dose for the IM route, or 30 mg per dose for the IV route in some protocols), which may be repeated every 6 hours as needed. The maximum daily dose in pediatric patients is generally 60 mg/day, and the maximum duration of parenteral treatment remains 2 days.

Pediatric dosing recommendations vary substantially between jurisdictions. In some countries, Toradol is not approved for pediatric use at all; in others, it is approved only for specific indications such as postoperative pain after surgery. Healthcare providers must refer to their local prescribing information and institutional guidelines. Toradol should not be used in neonates or infants under 2 years of age because of insufficient safety and efficacy data and because of developmental immaturity of renal function.

Elderly Patients (65 Years and Older)

Elderly patients are at substantially increased risk for NSAID-related adverse effects, including gastrointestinal bleeding, renal impairment, and cardiovascular events. For patients aged 65 years and older, the dose of Toradol must be reduced. The recommended dose is 15 mg IM or IV, which may be repeated every 6 hours as needed, up to a maximum daily dose of 60 mg/day. The same dose reduction applies to patients weighing less than 50 kg, regardless of age, and to patients with any degree of renal impairment (creatinine clearance 30–60 ml/min or elevated serum creatinine).

In elderly patients, additional monitoring is warranted, including serum creatinine, blood pressure, and observation for early signs of gastrointestinal bleeding (unexplained anemia, melena, abdominal discomfort). Concomitant prescription of a proton-pump inhibitor is often appropriate. The duration of Toradol therapy in elderly patients should be kept as short as clinically acceptable, and alternative analgesic strategies should be considered at the earliest opportunity.

Missed Dose

Because Toradol injection is administered by healthcare professionals in hospitals, emergency departments, and surgical centers, missed doses are uncommon. If a scheduled dose is missed, it should be given as soon as it is recognized, provided the minimum 6-hour dosing interval between doses is maintained. The missed dose must not be doubled to compensate. If significant time has elapsed since the scheduled dose, the healthcare provider should reassess whether Toradol remains necessary or whether an alternative analgesic strategy (including transition to oral ketorolac or non-NSAID analgesics) is more appropriate.

Overdose

Overdose with Toradol can produce a range of symptoms depending on the amount administered and the patient's underlying condition. Symptoms of ketorolac overdose include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, headache, tinnitus, and metabolic acidosis. In severe overdose, patients may develop acute renal failure, hepatic dysfunction, respiratory depression, hypotension, coma, and, in rare cases, multi-organ failure. There have been occasional reports of fatal outcomes following massive NSAID overdose.

There is no specific antidote for Toradol overdose, and management is primarily supportive. For recent oral ingestion of ketorolac tablets within 1 hour (not applicable to parenteral overdose), gastric decontamination with activated charcoal may be considered. Treatment includes close monitoring of vital signs, renal function, electrolytes, and acid-base status; administration of intravenous fluids to maintain hydration and urine output; and management of gastrointestinal bleeding with proton-pump inhibitors if indicated. Because of ketorolac's high plasma protein binding (over 99%) and relatively low volume of distribution, hemodialysis does not significantly enhance drug clearance and is not recommended as a treatment for overdose.

What Are the Side Effects of Toradol?

Like all NSAIDs, Toradol can produce a spectrum of adverse effects that vary in frequency and severity. Understanding this side effect profile is essential for healthcare providers and patients to enable early recognition and appropriate management. The adverse effects of Toradol are classified by frequency based on pooled data from clinical trials and extensive post-marketing surveillance conducted over more than three decades of clinical use.

The incidence of many adverse effects — particularly gastrointestinal, renal, and cardiovascular complications — is strongly correlated with both the dose of Toradol used and the duration of treatment. This dose- and duration-dependent risk profile is the foundational reason for the strict limits on treatment duration. Patients who receive Toradol within the recommended dose and duration guidelines have a substantially lower risk of serious complications than those who exceed these limits. However, even within the recommended parameters, Toradol carries a higher absolute risk of gastrointestinal bleeding than most other NSAIDs.

The classification below uses standard frequency categories recognized by regulatory authorities: Very common (affects more than 1 in 10 patients), Common (1 in 10 to 1 in 100), Uncommon (1 in 100 to 1 in 1,000), and Rare (fewer than 1 in 1,000).

Patients must be advised to seek immediate medical attention if they experience any signs of gastrointestinal bleeding (black or tarry stools, vomiting blood or material resembling coffee grounds, unexplained severe abdominal pain), allergic or anaphylactic reactions (difficulty breathing, swelling of the face, lips or throat, severe skin rash, rapid heartbeat, faintness), cardiovascular events (chest pain, sudden weakness on one side of the body, slurred speech, vision changes), renal problems (significantly decreased urine output, unusual swelling of legs or feet, unexplained weight gain), or severe skin reactions (blistering, peeling rash, painful mouth sores).

Healthcare providers are strongly encouraged to report suspected adverse reactions through their national pharmacovigilance systems. In the European Union, reporting is coordinated through national competent authorities; in the United States, adverse events can be submitted to the FDA MedWatch program; in the United Kingdom, reports go to the Yellow Card Scheme maintained by the Medicines and Healthcare products Regulatory Agency. Post-marketing surveillance continues to play a critical role in monitoring Toradol's safety profile and identifying rare adverse effects that may not have been detected in pre-approval clinical trials.

How Should You Store Toradol?

Proper storage of Toradol is essential to preserve the stability, sterility, and pharmacologic potency of the medication. Toradol solution for injection should be stored at controlled room temperature not exceeding 25°C (77°F). The ampoules or single-use vials should be kept in their original outer packaging to protect the solution from light, as ketorolac tromethamine can undergo photodegradation when exposed to direct sunlight or strong artificial light over prolonged periods. Light exposure can alter the chemical composition of the drug and reduce its efficacy, though the formulation is reasonably stable under typical indoor lighting conditions for the brief durations involved in clinical handling.

The solution must never be frozen. Freezing can alter the physical and chemical properties of the formulation, potentially compromising sterility and potency. If Toradol has been inadvertently frozen, it should be discarded and not used, even if it appears visually normal after thawing. Once thawed solutions can harbor microscopic crystals or degradation products that are not visible to the naked eye.

Before administration, each ampoule or vial should be visually inspected for clarity, color, and the absence of particulate matter. Toradol solution is normally a clear, colorless to slightly yellow solution. If the solution appears cloudy, has an unexpected color, or contains visible particles or precipitate, it must not be used. The product is packaged in single-use glass ampoules or vials, without preservatives; any unused portion remaining after a dose has been withdrawn should be discarded immediately and must not be stored for subsequent use. This is particularly important because the absence of preservatives means that contamination can promote microbial growth.

As with all medications, Toradol should be kept out of the sight and reach of children, although in practice the drug is almost exclusively stored in secured medication cabinets in hospitals, emergency departments, and clinics rather than in home settings. Do not use Toradol after the expiration date printed on the ampoule and outer packaging; the expiration date refers to the last day of the indicated month. Healthcare facilities should follow their institutional policies for medication storage, including continuous temperature monitoring and first-in, first-out stock rotation to ensure that expired products are not inadvertently administered. Pharmaceutical waste, including unused or expired ampoules, should be disposed of in accordance with local regulations and institutional protocols; sharps (including opened ampoules and used syringes) must go into designated sharps containers.

What Does Toradol Contain?

The active ingredient in Toradol is ketorolac tromethamine (also known internationally as ketorolac trometamol), present at a concentration of 30 mg per milliliter of solution. Ketorolac tromethamine is the tromethamine (tris) salt of ketorolac, which improves aqueous solubility and chemical stability compared with the parent compound. Chemically, ketorolac belongs to the pyrrolizine carboxylic acid class and is a structural analog of tolmetin and zomepirac. The drug is supplied as a racemic mixture of the R-(+) and S-(-) enantiomers in a 1:1 ratio; the analgesic and anti-inflammatory activity resides almost entirely in the S-(-) enantiomer, which is approximately 100 times more potent as a COX inhibitor than the R-(+) enantiomer. The molecular formula of ketorolac tromethamine is C₁₉H₂₄N₂O₆, with a molecular weight of 376.41 g/mol.

The excipients (inactive ingredients) in the Toradol injection formulation serve important pharmaceutical functions, ensuring that the product can be safely and effectively administered:

• Sodium chloride: Added to adjust the tonicity (osmolality) of the solution so that it is approximately isotonic with body fluids (around 290–310 mOsm/kg). An isotonic solution minimizes pain and local tissue irritation at the injection site and prevents the mechanical injury to red blood cells that could occur with hypotonic or hypertonic injections.
• Ethanol (small quantity): Present as a co-solvent, typically at concentrations of 0.1–10% depending on the specific formulation, to enhance the solubility and chemical stability of ketorolac tromethamine in the aqueous vehicle. The absolute amount of ethanol in a clinical dose is extremely small and has no pharmacologic effect.
• Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment during manufacturing. The final solution is buffered to a pH range of approximately 6.9–7.9, which is close to physiological pH (7.35–7.45) and minimizes tissue irritation, hemolysis, and vascular discomfort upon injection.
• Water for injections: The vehicle (solvent) for the formulation, prepared to meet strict pharmacopoeial standards for purity, sterility, and freedom from endotoxins (pyrogens). Water for injections is the highest-grade pharmaceutical water and is required for all parenteral preparations.

Notably, Toradol injection does not contain preservatives. The absence of preservatives is important for minimizing the risk of preservative-related hypersensitivity reactions and is consistent with the single-use nature of the product. It also means, however, that the contents of an opened ampoule or vial must be used immediately; any unused portion must be discarded rather than stored for later use.

Patients with known hypersensitivity to any of the listed ingredients should not receive Toradol. Patients with a history of sensitivity to ethanol, polysorbates, or other commonly used excipients should review the specific excipient profile of their Toradol product with their pharmacist, as formulations can differ slightly between manufacturers and countries. The extremely small quantity of ethanol in the injection is clinically insignificant from an intoxication standpoint but could still theoretically trigger hypersensitivity in extremely sensitive individuals.